文献速递乳腺癌

帕博利珠单抗治疗早期三阴性乳腺癌中按残留癌症负荷评估的无事件生存:KEYNOTE-522探索性分析

Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
PubMed 文献 · Ann Oncol · 2024-02-17

KEYNOTE-522预设探索性分析纳入1174例高危早期三阴性乳腺癌患者,随机2:1接受帕博利珠单抗或安慰剂联合化疗。帕博利珠单抗使患者向更低残留癌症负荷(RCB)类别转移,RCB-2组无事件生存获益最大(HR 0.52,95%CI 0.32-0.82)。

要点

  • 帕博利珠单抗使更多患者达到RCB-0(病理学完全缓解),RCB-1、RCB-2、RCB-3患者减少。
  • RCB-2组无事件生存HR 0.52(95%CI 0.32-0.82),为各RCB类别中获益最大。
  • RCB-0/1组中超过半数事件为中枢神经系统复发,帕博利珠单抗组13/22(59.1%)vs 安慰剂组8/16(50.0%)。

核心结论

  • 在化疗基础上加用帕博利珠单抗使RCB-0、RCB-1和RCB-2类别的无事件生存事件减少,其中RCB-2获益最大。
  • 帕博利珠单抗不仅提高病理学完全缓解率,还改善了大多数未达病理学完全缓解患者的无事件生存。

研究设计与样本

  • KEYNOTE-522预设探索性分析,纳入1174例T1c/N1-2或T2-4/N0-2期三阴性乳腺癌患者,随机2:1分组。
  • 帕博利珠单抗200 mg或安慰剂每3周联合四个周期紫杉醇+卡铂,序贯四个周期多柔比星或表柔比星+环磷酰胺。
  • 术后帕博利珠单抗或安慰剂治疗九个周期或直至复发或不可接受毒性。
  • 主要终点为病理学完全缓解和无事件生存,RCB为预设探索性终点,采用Cox回归模型评估无事件生存与RCB的关联。

主要发现

  • 帕博利珠单抗组RCB-0(病理学完全缓解)患者更多,RCB-1、RCB-2、RCB-3患者更少。
  • 无事件生存的风险比(95%CI)分别为RCB-0 0.70(0.38-1.31)、RCB-1 0.92(0.39-2.20)、RCB-2 0.52(0.32-0.82)、RCB-3 1.24(0.69-2.23)。
  • 最常见的首次无事件生存事件为远处复发,帕博利珠单抗组在所有RCB类别中均较少。
  • RCB-0/1组中超过半数事件为中枢神经系统复发:帕博利珠单抗组13/22(59.1%),安慰剂组8/16(50.0%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: KEYNOTE-522 demonstrated statistically significant improvements in pathological complete response (pCR) with neoadjuvant pembrolizumab plus chemotherapy and event-free survival (EFS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with high-risk, early-stage triple-negative breast cancer (TNBC). Prior studies have shown the prognostic value of the residual cancer burden (RCB) index to quantify the extent of residual disease after neoadjuvant chemotherapy. In this preplanned exploratory analysis, we assessed RCB distribution and EFS within RCB categories by treatment group. PATIENTS AND METHODS: A total of 1174 patients with stage T1c/N1-2 or T2-4/N0-2 TNBC were randomized 2 : 1 to pembrolizumab 200 mg or placebo every 3 weeks given with four cycles of paclitaxel + carboplatin, followed by four cycles of doxorubicin or epirubicin + cyclophosphamide. After surgery, patients received pembrolizumab or placebo for nine cycles or until recurrence or unacceptable toxicity. Primary endpoints are pCR and EFS. RCB is a prespecified exploratory endpoint. The association between EFS and RCB was assessed using a Cox regression model. RESULTS: Pembrolizumab shifted patients into lower RCB categories across the entire spectrum compared with placebo. There were more patients in the pembrolizumab group with RCB-0 (pCR), and fewer patients in the pembrolizumab group with RCB-1, RCB-2, and RCB-3. The corresponding hazard ratios (95% confidence intervals) for EFS were 0.70 (0.38-1.31), 0.92 (0.39-2.20), 0.52 (0.32-0.82), and 1.24 (0.69-2.23). The most common first EFS events were distant recurrences, with fewer in the pembrolizumab group across all RCB categories. Among patients with RCB-0/1, more than half [21/38 (55.3%)] of all events were central nervous system recurrences, with 13/22 (59.1%) in the pembrolizumab group and 8/16 (50.0%) in the placebo group. CONCLUSIONS: Addition of pembrolizumab to chemotherapy resulted in fewer EFS events in the RCB-0, RCB-1, and RCB-2 categories, with the greatest benefit in RCB-2. These findings demonstrate that pembrolizumab not only increased pCR rates, but also improved EFS among most patients who do not have a pCR.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Pusztai L, Denkert C, O'Shaughnessy J, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol. 2024. PMID: 38369015. doi:10.1016/j.annonc.2024.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。